Recent Updates
Recently added Catalysts
ABSI Positive Sentiment

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

Tuesday, July 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Absci Corporation, a clinical-stage biopharmaceutical company, has announced it will report its business updates along with financial and operating results for the second quarter of 2026 on August 11, 2026. The company focuses on developing innovative therapeutics using generative AI technology. This announcement reflects Absci's commitment to keeping stakeholders informed.
Price reaction · baseline $10.23 (2026-07-14 close) · hit after-hours · clean, no other ABSI news in the window
day 0 close · peak
-4.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Absci is advancing breakthrough therapeutics.
  • The company is utilizing generative AI in its processes.
  • Upcoming report indicates transparency and engagement with stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+405%
120-day peak, hindsight
Typical move
13.1%
average across 4 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
ABS-201
Phase 1 · Androgenetic Alopecia (AGA)

Full Press Release Details

VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results

Frequently Asked Questions

When will Absci report its Q2 2026 results?

Absci will report its Q2 2026 financial and operating results on August 11, 2026.

What is Absci Corporation focused on?

Absci Corporation is focused on advancing breakthrough therapeutics using generative AI.

ShareAdd on Google
Tags: ABSI Viatris Investor Conferences Healthcare Absci biopharmaceutical generative AI financial results clinical-stage
Last updated: Jul 14, 2026

Biotech snapshot

Cash runway
$201M liquidity · $9M/mo burn
~21 mo
Low dilution risk
Lead asset
ABS-201Phase 1
Androgenetic Alopecia (AGA) →

Catalyst track record

+405%
best trade around ABSI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ABSI.

See every catalyst's timing & PoA →